Vialogy Share Discussion Threads

[ewads] 14/6/2014 07:50

gwr7 - he will probably say that it's just his opinion, and everyone makes his own decisions. Just strikes me that the Premaitha merger has only just been made public to VIY shareholders and he's singing the praises from the rooftops.
If you keep on day after day it eventually sticks? He's a good antidote to realistic but depressive Twix......

A lot of former investors only have the choice to either do some research,follow like sheep, or get out.

A quick glance makes the proposition with Premaitha interesting. Just IONA(R) to offer the market at some future stage. It would appear to have a demand and be quite unique in a $3b market?

Wonder what F11 makes of this.

As someone mentioned before, its now bio snakeoil as opposed to digital.

As I got so disillusioned with the old BOD I'll just let my holding run with the sheep.

[gwr7] 14/6/2014 06:10

I see The Siren is still luring hapless investors onto the rocks. Be mindful that he wrote tens if not hundreds of thousands of words about Vialogy. Ask yourself why anyone would spend so much time and effort promoting a basket case. You would have to be either paid to do it or insane. How much Prophet did he make for anyone buying the rubbish he spouted on Vialogy? Given his appalling track record there why would anyone be interested in a word he says?

[the prophet] 14/6/2014 00:30

DVIThanks for that. Yes, some folks been saving their vitriol up for five years! Water of a ducks back to me, we all have to be responsible for our own investment decisions, a concept some seem to struggle with.Anyway, I prefer to look forwards. I think your analysis is correct, existing VIY holders throwing in the towel. I think this is going to do well, not without it's risks, ofcourse, but the background to the new incumbents gives solid reasons for optimism.This BB is useful in one respect, the number of investors banging on about the past/bond/board/QRD is great, they completely and 100% miss the point that it has absolutely nothing to do with Premaitha. I was very happy to pick up more sub .15p and hope get another opportunity next week! Will also be applying for excess in the open offer. Interesting MW piece tonight, apparently the board have put over £1m of their own dosh in. Given their background and that fact, happy to follow the guys in.Re research note, yes, there will be one. Don't forget Premaitha not listed till post the GM 3rd July. I think we will see a note a few months after the listing.

[sunsetwarrior] 13/6/2014 22:05

busyderek
I read everything that MW put out about VIY. He was always very cautious and always said it was very high risk. He also strongly advises the use of a stop loss. Wish I'd listened.

[deepvalueinvestor] 13/6/2014 22:02

The prophet, you certainly got some stick today but the QRI story was compelling and I value your input.I liked the price action this afternoon after unhappy viy holders dumped their shares this morning.I wouldn't be surprised to the share price move up from here. I just hope we get a thoughtful research note so that I can justify adding.

[busyderek] 13/6/2014 21:36

Sw, you should have read the tripe mw put out about viy, tread with caution i say. Tp - its nothing to me, just asking. Thanks for answering :)

[sunsetwarrior] 13/6/2014 20:34

Just read MWs latest note on VIY. I can see why you're so positive TP. It does look promising. I might treat myself to few on Monday.

[the prophet] 13/6/2014 20:02

bdMW posted that it 'could' be this week. What's it to you?

[busyderek] 13/6/2014 18:44

So tp, how did you know news was coming this week?

[the prophet] 13/6/2014 18:23

I would agree, need to treat each investment on its merits. Gawd knows why folks bring up Meldex, you might as well name any company in the stock market that has done good bad or indifferent. Is that anything at all to do with Premaitha and will it have any bearing at all on how Premaitha does? Answer is obviously no.Premaitha will stand or fall on its own merits, but worth investors checking out the background and track record of Premaitha. That should give a clue as to where this could be heading.I tend to think a lot of comments today are just ill informed based on VIY's past, which has nothing to do with Premaitha's future. Worth investors reading the admission document fully ,imo, if they want to learn something about the background and track record of the new team together with details of Premaitha's markets, technology, strategy etc etc.

[greenpastures2] 13/6/2014 17:34

twix, I would like to know why QRD was never commercialised. Did SG string us along? We cannot be sure of that at the moment.

I did regret at the time a few years ago not challenging TB when he justified the generous salary for SG. I have not been so reticent to speak up at agms since.

Don't make the mistake of feeling that you need to average down to reduce your losses. Treat each investment on its merits. Meldex promoted its loan notes on the basis that it was a chance to average down and those who did now regret it.

[twix386] 13/6/2014 16:55

rankles a lot, but at least SG is no longer on the Vialogy BOD.

SGLFLS has been removed from creaming off AR's efforts. hooray!
Perhaps he'll do something after 8 months of VEC nada!
What a waste of a reputation!!

[ewads] 13/6/2014 16:36

Agree VIY old company has been written off. QRD is not the future we thought it would be. It does rankle a little bit that our hard earned, has and still is, supporting a decent lifestyle for the few.

[spec7] 13/6/2014 14:45

Waterkloo, most people holdings are so small after all this (in value) i dont think anyone is really bothered, might as well just let it ride for the sake of a few £ks, thats my feeling anyway. Basically this is written off.

[spec7] 13/6/2014 14:41

someone bought 23m. but the share price now reflects the discounted price set by the management not the traded volumes

[waterloo01] 13/6/2014 14:41

Oh. Does anyone know much about the new market or done a SWOT? Who's the competition? Why not FDA (it's not that complex a process for non invasive)? What's the current BOD's experience in medical tech? What are the sales budgets? Who are the partners? What's are the manufacturing issues? How are they going to get to market and at what price/volume? (and a load more)

Surely after taking it on the chin for years re VIY and it's fantasies, you won't make the same mistake again of investing without fully understanding the company or will you?

It's not even like averaging down (almost ALWAYS a mistake). It's a 'new' company so you should treat any investment as if it's completely new to you.IMO.

[the prophet] 13/6/2014 14:05

sorry,what are you on about? I bought 5m shares @.1479p, it will be in the trades page or whatever.
I've been posting on these boards for more years than I care to remember, have met many interesting and informative posters along the way, both in person at agm's, meets etc etc and via the boards but you do get a funny minority on these boards as well. Not sure what your problem is scottie.

[scottie01] 13/6/2014 13:54

The prophet.care to post the 5m trade details?you're either a complete clown or something more sinister IMO.

[the prophet] 13/6/2014 13:51

Spec

its all there on page 17

[the prophet] 13/6/2014 13:48

-spec , its all in the documentation, we still own 75% of VEC, its all there in black and white. Clearly its no longer core but if SG does a 'rave from the grave' and gets funding, VIY/Premaitha will still benefit.

[spec7] 13/6/2014 13:33

Thats my point though TP
QRD has been "forgotten about" but fact is if SG does get funding and its resurrected even in a year or ten what is our stake. We should at least be told. Happy to wave goodbye to QRD and VIY but if VIY no longer exists then does our 70% stake in VEC or qrd no longer exist as well.

[the prophet] 13/6/2014 13:21

Premaitha Health, which is based at Manchester's Science Technology Park, has agreed terms to join ViaLogy, an investment company listed on the London Stock Exchange.



Biotechnology company Premaitha Health has today announced it will be joining the London Stock Exchange as it gears up to merge with another firm.

Premaitha Health, which is based at Manchester's Science Technology Park, has agreed terms to join ViaLogy, an investment company listed on the London Stock Exchange.

Subject to ViaLogy shareholders approval later this month, the enlarged business will be re-named Premaitha Health PLC and will become a listed company on the AIM platform.

Premaitha is also in the process of launching its first product, the IONA Test.

The prenatal screening test, which will be offered to pregnant women, determines the risk of Down's Syndrome or other serious genetic diseases, without risk to the fetus.

Premaitha chief executive Dr Stephen Little, said: "Our approach is to take early stage discoveries and translate them into clinically useful diagnostic products that can be widely used to benefit human health.

"As we build and commercialise the IONA Test, we are not only building a valuable in vitro diagnostic product in its own right but also establishing a template for creating valuable diagnostic content on third parties' next generation sequencing systems."

Dr Little added: "The global market for prenatal testing is estimated at $4.2bn and this is an exciting phase in our development of the business roll-out so we are looking forward to working with the new team and delivering on our plans for the IONA Test."

The technology used in the IONA Test will be new to many potential customers.

Premaitha is in the process of establishing a demonstration laboratory at its Manchester headquarters.

This laboratory will reproduce the complete IONA Test workflow so that customers can test their own samples and be trained in the process.

The team of scientists and technicians at Premaitha are also currently undergoing IONA Test development and design verification processes, which is expected to be completed by the end of September.

The clinical performance and commercialisation testing is then anticipated to be complete by the end of this year with a commercial launch commencing next January.

Premaitha is targeting its product at 600 laboratories offering prenatal screening within the EMEA region as well as similar labs throughout the rest of the world.

[the prophet] 13/6/2014 13:18

Spec7
-we've still got our share of VEC, but its unlikely to be worth much/anything, as SG can't seem to get funding for it.

What a lot of posters who are banging on about bond/quantumRD/the past don't seem to realise is this is now a new company with a new bod. VIY failed, and this is a second bite. Premaitha has nothing to do with VIY, other than VIY is being used as a shell for the AIM listing.

I am very happy with the current situation.